Skip to main content
Figure 3 | Virology Journal

Figure 3

From: FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection

Figure 3

Single or multiple FSL-1 dosing did not induce organ enlargement. As an additional measure of peripheral immunotoxicity, immune cell migration was evaluated by gross observation of associated lymphoid tissues following FSL-1 application. GLN, liver and spleen weights for organs collected 2 or 5d after delivery of FSL-1 (6 μg; closed square) or DPBS vehicle (60 μL; open circle) in a single or 5 multiple once daily doses. By organ, the mean % of total body weight for each group is demarcated by the horizontal line with each point representing one mouse (n = 5/group). Weights of organs collected 2d after the last of 5 consecutive daily FSL-1 doses were not significantly (p > 0.05; Student's t-test) different than organs collected from mice treated with an equivalent volume of the DPBS vehicle. Similar statistically (p > 0.05; Student's t-test) indistinguishable results were observed for organs collected 2 or 5d after a single FSL-1 dose (data not shown). Groups were compared for statistical significance by one-way ANOVA.

Back to article page